AU3031097A - Use of preparations containing opiate antagonists and agonists for the prevention and therapeutic treatment of migraines - Google Patents

Use of preparations containing opiate antagonists and agonists for the prevention and therapeutic treatment of migraines

Info

Publication number
AU3031097A
AU3031097A AU30310/97A AU3031097A AU3031097A AU 3031097 A AU3031097 A AU 3031097A AU 30310/97 A AU30310/97 A AU 30310/97A AU 3031097 A AU3031097 A AU 3031097A AU 3031097 A AU3031097 A AU 3031097A
Authority
AU
Australia
Prior art keywords
migraines
agonists
prevention
therapeutic treatment
preparations containing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU30310/97A
Other languages
English (en)
Inventor
Heribert Bohlen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
VIVA DIAGNOSTIKA DIAGNOSTISCHE PRODUKTE GmbH
Original Assignee
VIVA DIAGNOSTIKA DIAGNOSTISCHE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by VIVA DIAGNOSTIKA DIAGNOSTISCHE filed Critical VIVA DIAGNOSTIKA DIAGNOSTISCHE
Publication of AU3031097A publication Critical patent/AU3031097A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU30310/97A 1996-06-07 1997-05-30 Use of preparations containing opiate antagonists and agonists for the prevention and therapeutic treatment of migraines Abandoned AU3031097A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19622866 1996-06-07
DE19622866A DE19622866C2 (de) 1996-06-07 1996-06-07 Verwendung von Opiat-Antagonisten und -Agonisten enthaltende Präparationen zur Prophylaxe und therapeutischen Behandlung von Migräne und Migräne-verwandten Erkrankungen
PCT/EP1997/002823 WO1997047293A1 (de) 1996-06-07 1997-05-30 Verwendung von opiat-antagonisten und -agonisten enthaltenden präparationen zur prophylaxe und therapeutischen behandlung von migräne

Publications (1)

Publication Number Publication Date
AU3031097A true AU3031097A (en) 1998-01-07

Family

ID=7796378

Family Applications (1)

Application Number Title Priority Date Filing Date
AU30310/97A Abandoned AU3031097A (en) 1996-06-07 1997-05-30 Use of preparations containing opiate antagonists and agonists for the prevention and therapeutic treatment of migraines

Country Status (3)

Country Link
AU (1) AU3031097A (de)
DE (1) DE19622866C2 (de)
WO (1) WO1997047293A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5855907A (en) * 1997-03-24 1999-01-05 Peyman; Gholam A. Method of treatment of migraine
US5900420A (en) * 1997-06-19 1999-05-04 Cole; William L. Method for treating chronic fatigue syndrome and fibromyalgia with buprenorphine
US6096738A (en) * 1999-01-28 2000-08-01 Winston Laboratories, Inc. Method for treatment of headache

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995032973A1 (en) * 1994-05-31 1995-12-07 Mallinckrodt Chemical, Inc. The preparation of nalbuphine having low levels of beta-epimer

Also Published As

Publication number Publication date
DE19622866A1 (de) 1997-12-11
WO1997047293A1 (de) 1997-12-18
DE19622866C2 (de) 1998-12-24

Similar Documents

Publication Publication Date Title
HUP9904361A3 (en) Use of isobutylgaba and its derivatives for the treatment of pain
IL127189A0 (en) Compositions methods and devices for the transdermal delivery of drugs
EP0983482A4 (de) Vorrichtung zur gefässabbildung und zugehörige anwendungsverfahren
IL125735A0 (en) Pharmaceutical compositions for the treatment of glaucoma
PL330814A1 (en) Compounds for and methods of delivering pharmaceutical preparations and their application
IL112969A0 (en) Pharmaceutical composition comprising t-cell actiVator for the treatment of cancer
HUP0003851A3 (en) Pharmaceutical composition for the treatment or prevention of glomerulopathy
EP0750909A4 (de) Verwendung von amino-hydrierten chinazolinverbindungen und ihren derivaten zur entwöhnung bei drogenabhängigkeit
GB2311940B (en) Pharmaceutical compositions for the treatment of rhinitis
AU1575697A (en) Compositions and methods for the treatment and diagnosis of cancer
HUP0003428A3 (en) Use of leptin antagonists for the treatment of diabetes
AU4774597A (en) Use of 1-hydroxy-2-pyridones for the treatment of skin infections
IL126683A0 (en) Pharmaceutical composition and method for the treatment of severe blood loss and for the inhibition or treatment of hemorrhagic shock
AU2821295A (en) Compositions and methods for the treatment of tumors
IL127739A0 (en) Retinoyloxy (substituted) alkylene butyrates useful for the treatment of cancer and other proliferative diseases
AU5526898A (en) Isomeric pharmaceutical formulation containing dfmo for the treatment of cancer
IL121329A (en) Pharmaceutical composition for the treatment of cancer comprising somatostatin2 and other peptides
AU6786898A (en) Methods and compositions for the diagnosis and treatment of neuropsychiatric di sorders
AU3031097A (en) Use of preparations containing opiate antagonists and agonists for the prevention and therapeutic treatment of migraines
AU6786598A (en) Methods and compositions for the diagnosis and treatment of neuropsychiatric di sorders
HU0500865D0 (en) Use of teophyllin derivatives for the preparation of pharmaceutical compositions for the prevention and treatment of shock
IL112681A0 (en) Opioid peptides for the treatment of pain and use thereof
AU6786798A (en) Methods and compositions for the diagnosis and treatment of neuropsychiatric di sorders
AU8580598A (en) Methods and compositions for the diagnosis and treatment of neuropsychiatric di sorders
AU2750297A (en) Methods for prevention and/or treatment of neutropenia